# A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

> **NCT04640025** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Incyte Corporation** · enrollment: 18 (actual)

## Conditions studied

- Myelofibrosis
- Postlung Transplant (Bronchiolitis Obliterans)
- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** itacitinib

## Key facts

- **NCT ID:** NCT04640025
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-10
- **Primary completion:** 2026-06-22
- **Final completion:** 2026-06-22
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640025, "A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04640025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*